Description
PharmaQo Arimidex 1 delivers 1 mg Anastrozole per oral tablet, packaged in 50-tablet packs for research use. Anastrozole is a nonsteroidal aromatase inhibitor under investigation for its role in reducing estrogen production, making it valuable in research on hormone-sensitive cancers, endocrine modulation, and post-cycle estrogen management models.
It is known for effectively lowering circulating estrogen levels without significant androgenic or progestogenic activity.
Product Details:
Active Ingredient:
-
Anastrozole (Arimidex)
Concentration: 1 mg per tablet
Form: Oral tablets
Packaging: 50 tablets per pack
Pharmacokinetics:
Anastrozole has an oral half-life of ~46–48 hours, allowing for once-daily dosing in most research designs.
Usage Recommendations:
-
Indications (Research Context): Investigational use in estrogen suppression, hormone-sensitive tumor models, post-cycle hormone regulation (not approved for human use)
-
Typical Dosage (Research Use): 0.5–1 mg per day, depending on study protocol
-
Monitoring: Estrogen levels, lipid profile, bone density, liver function
-
Cycle/Duration: As determined by research objectives
Disclaimer:
This product is intended strictly for research and educational purposes. It is not for human consumption or therapeutic use. Not suitable for individuals under 18, pregnant or breastfeeding women, or those with medical risks. Always follow local research regulations and ethical standards.